[go: up one dir, main page]

WO2012007758A3 - Pharmaceutical formulations - Google Patents

Pharmaceutical formulations Download PDF

Info

Publication number
WO2012007758A3
WO2012007758A3 PCT/GB2011/051322 GB2011051322W WO2012007758A3 WO 2012007758 A3 WO2012007758 A3 WO 2012007758A3 GB 2011051322 W GB2011051322 W GB 2011051322W WO 2012007758 A3 WO2012007758 A3 WO 2012007758A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical formulations
processes
pharmaceutical
reducing
particle size
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2011/051322
Other languages
French (fr)
Other versions
WO2012007758A2 (en
Inventor
Lars-Erik Briggner
Lennart Lindfors
Craig Michael Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca UK Ltd
AstraZeneca AB
Original Assignee
AstraZeneca UK Ltd
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca UK Ltd, AstraZeneca AB filed Critical AstraZeneca UK Ltd
Publication of WO2012007758A2 publication Critical patent/WO2012007758A2/en
Publication of WO2012007758A3 publication Critical patent/WO2012007758A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to processes for reducing the particle size of active pharmaceutical ingredients and to pharmaceutical compositions and pharmaceutical formulations prepared by these processes.
PCT/GB2011/051322 2010-07-15 2011-07-14 Pharmaceutical formulations Ceased WO2012007758A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36442810P 2010-07-15 2010-07-15
US61/364,428 2010-07-15

Publications (2)

Publication Number Publication Date
WO2012007758A2 WO2012007758A2 (en) 2012-01-19
WO2012007758A3 true WO2012007758A3 (en) 2012-07-12

Family

ID=44629444

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2011/051322 Ceased WO2012007758A2 (en) 2010-07-15 2011-07-14 Pharmaceutical formulations

Country Status (1)

Country Link
WO (1) WO2012007758A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20221540T1 (en) 2016-06-20 2023-03-03 Shionogi & Co., Ltd. Method for producing substituted polycyclic pyridone derivative and crystal of same
GB201714777D0 (en) * 2017-09-14 2017-11-01 Univ London Queen Mary Agent
EP4396167A2 (en) * 2021-09-02 2024-07-10 Conduit UK Management Ltd Therapeutic cocrystals of 3-{[5-(azetidine-1-ylcarbonyl)pyrazin-2-yl]oxy}-5-{[(1 s)-1 -methyl-2- (methyloxy)ethyl]oxy)-n-(5-methylpyrazin-2-yl)benzamide

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007007041A1 (en) * 2005-07-09 2007-01-18 Astrazeneca Ab Heteroaryl benzamide derivatives for use as glk activators in the treatment of diabetes

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007007041A1 (en) * 2005-07-09 2007-01-18 Astrazeneca Ab Heteroaryl benzamide derivatives for use as glk activators in the treatment of diabetes

Also Published As

Publication number Publication date
WO2012007758A2 (en) 2012-01-19

Similar Documents

Publication Publication Date Title
WO2012021715A3 (en) Stable formulations of linaclotide
WO2010084480A3 (en) Delivery particles
WO2010079467A3 (en) Delivery particles
WO2010079466A3 (en) Delivery particles
WO2010079468A3 (en) Delivery particle
WO2012112410A3 (en) Micronized placental tissue compositions and methods for making and using the same
WO2011017502A3 (en) Linaclotide-containing formulations for oral administration
WO2011093832A3 (en) Stable efervescent formulations comprising cefaclor
WO2010092090A3 (en) Novel salts of sitagliptin
WO2011157720A3 (en) Ivabradine-containing pharmaceutical composition with modified release
HK1213779A1 (en) Composition for immediate and extended release
WO2013134534A3 (en) Solid state forms of cabazitaxel and processes for preparation thereof
WO2013057741A3 (en) Pharmaceutical compositions of ursodeoxycholic acid
WO2014068586A3 (en) Solid oral compositions of tolvaptan
WO2012075015A3 (en) Oral metronidazole pharmaceutical compositions
PL2582359T3 (en) Solid compositions in form of powders or granulates for the oral administration of active ingredients and method for obtaining them
WO2014064652A3 (en) Stable pharmaceutical composition of peginterferon alpha-2b
WO2013170086A3 (en) Formulations for the delivery of active ingredients
WO2012093973A3 (en) Compositions in the form of tablets comprising acarbose
WO2014166836A8 (en) Growth hormone compound formulation
WO2011139249A3 (en) Pharmaceutical composition comprising cefdinir
WO2013100718A3 (en) Pharmaceutical composition for preventing or treating inflammatory diseases or asthma, containing lagerstroemia ovalifolia extract or fraction thereof as active ingredient
WO2012007758A3 (en) Pharmaceutical formulations
MX2013013079A (en) Compositions comprising antibacterial agent and tazobactam.
WO2011093831A3 (en) Effervescent formulations comprising cefprozil as active agent

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11738786

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11738786

Country of ref document: EP

Kind code of ref document: A2